CliffBio
biologic

Fluad,Fluad Quadrivalent

Influenza Vaccine, Adjuvanted

Loss of exclusivityFebruary 2032projected — 12-year biologic exclusivity estimate
CompanySeqirus →See this company's full patent-cliff portfolio

Drug detail

Brand nameFluad,Fluad Quadrivalent
Active ingredientInfluenza Vaccine, Adjuvanted
Strength60UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2020
Marketing statusRx

More from Seqirus

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Fluad,Fluad Quadrivalent patent cliff — loss of exclusivity February 2032 | CliffBio